Issue link: https://www.e-digitaleditions.com/i/666166
www.drpharm-USA.com p Dr. Pharm YouTube Right Stuff Equipment's Center for Excellence Parts and Service Denver, CO. For more information (866)778-7826 tbellio@rightstuffequipment.com www.bjhanlin.com VISIT OUR NEW WEB SITE!!! Dr. Pharm carries a complete line of solid dose manufacturing equipment including Capsule Fillers /Tablet Presses/Coaters/Fluid Bed Dryers/Wet Granulators/Blenders All machines are cGMP and FDA compliant Visit us in Booth 2964 at the InterPhex Show in New York April 26-28 for patients age 12 or older who meet certain conditions, including no his- tory of antiretroviral treatment. It is Gilead's second tenofovir alafe- namide-based treatment approved by the Agency and is the smallest pill of any single-tablet HIV treatment. US drug spending increases to nearly 13 percent in 2014 WASHINGTON, DC—Rising drug prices and the use of expensive specialty medicines accounted for a 12.6 percent increase in drug spend- ing in 2014, according to the Department of Health and Human Services. Additionally, prescription drug spending in the US increased to $457 billion in 2015, accounting for 16.7 percent of overall personal health care services. Of that total, the gov- ernment spent $20 billion to cover the cost of prescription drugs under Part B of Medicare. Officials are exploring options to lower the cost, including creating incentives for doctors to choose lower-cost therapies. Imprimis to offer compounded therapy alternative to Thiola SAN DIEGO, CA—Imprimis Pharmaceuticals plans to offer a delayed-release, compounded formu- lation as a lower-cost alternative to Thiola, which is prescribed to pre- vent cysteine kidney stone forma- tions. The company said the replace- ment, a combination of tiopronin and potassium citrate in a capsule, would cost about 70 percent less than Thiola, which costs $30 per tablet. The encapsulated compound is not FDA approved, and physicians would need to prescribe it to specific patients. Briefly noted… The FDA approved UCB's Briviact (brivaracetam) in combination with other drugs to treat partial onset seizures in patients age 16 years and older. It will be available in three for- mulations including film-coated tablets. The European Commission app - roved Teva Pharmaceutical's acquisi- tion of Allergan's global generic busi- ness. As part of approval, the company has agreed to divest certain overlapping molecules in 24 European countries. The company will divest most of Allergan generic business. The FDA approved Pfizer's Ibrance (palbociclib) in combination with fulvestrant to treat HR-positive, HER2-negative advanced breast can- cer in women who have recently undergone endocrine therapy. The once-daily capsule will be available to patients this month. The Agency also approved Pfizer's Xeljanz XR (tofacitinib citrate), a janus kinase (JAK) inhibitor treatment for moder- ate to severe rheumatoid arthritis (RA). The extended-release tablet is the first and once-daily oral JAK inhibitor treatment for RA. 12 April 2016 Tablets & Capsules